Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00642395 | Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT) | completed | Phase 2 | 61 | University Hospital, ToulouseOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT01206205 | Frontline Therapy in de Novo Multiple Myeloma Patients Under 65(IFM2008) | completed | Phase 2 | 31 | University Hospital, ToulouseOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT02260414 | Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer(METRO B) | completed | Phase 2 | 19 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | May 11, 2017 | clinicaltrials |
| NCT01056276 | Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy | completed | Phase 2 | 59 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT00530816 | Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma | completed | Phase 2 | 164 | AmgenINDUSTRY | 2 | May 2, 2017 | clinicaltrials |
| NCT02072863 | A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 9 | AmgenINDUSTRY | 3 | May 2, 2017 | clinicaltrials |
| NCT00681044 | HD Melphalan and SCT in Patients With IGDD or LCDD | terminated | Phase 2 | 5 | Boston Medical CenterOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01816620 | Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome | completed | Phase 2 | 41 | Peking Union Medical College HospitalOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02802163 | Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Apr 25, 2017 | clinicaltrials |
| NCT00109889 | S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 24, 2017 | clinicaltrials |
| NCT01884688 | UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma | completed | Phase 2 | 3 | University of ArkansasOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01351623 | Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 44 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT00636909 | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders(MINI HEME) | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 0 | Apr 6, 2017 | clinicaltrials |
| NCT01323751 | Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma(ACY-1215) | completed | Phase 1 / Phase 2 | 120 | CelgeneINDUSTRY | 1 | Apr 6, 2017 | clinicaltrials |
| NCT01534143 | High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant | terminated | Phase 2 | 1 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | terminated | Phase 2 | 14 | University of ArizonaOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT01207765 | Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma | terminated | Phase 2 | 8 | Tufts Medical CenterOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT00259740 | Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab | completed | Phase 2 | 96 | AmgenINDUSTRY | 0 | Mar 15, 2017 | clinicaltrials |
| NCT01484314 | Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma | terminated | Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00577642 | Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates | completed | Phase 2 | 29 | Massachusetts General HospitalOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00600353 | Multi-day Doses in Prevention of Nausea and Emesis | completed | Phase 2 | 20 | University of Kansas Medical CenterOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT00143845 | Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant | completed | Phase 2 | 54 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 8, 2017 | clinicaltrials |
| NCT00307086 | Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00091260 | CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 82 | Vaishali SanchorawalaOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00679367 | Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis(MRD) | completed | Phase 2 | 16 | Boston Medical CenterOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT01019174 | Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma(MM_LEN_DEX_CY) | completed | Phase 1 / Phase 2 | 40 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT02254551 | Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 7 | SCRI Development Innovations, LLCOTHER | 1 | Feb 16, 2017 | clinicaltrials |
| NCT02402725 | A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma(UltraDex) | withdrawn | Phase 2 | 0 | Boston Medical CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT02519114 | Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 24 | Maastricht University Medical CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00790647 | Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 10 | Boston Medical CenterOTHER | 1 | Feb 6, 2017 | clinicaltrials |
| NCT01029054 | Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT00075608 | 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis | terminated | Phase 2 | 12 | Boston Medical CenterOTHER | 1 | Jan 27, 2017 | clinicaltrials |
| NCT02578121 | UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | terminated | Phase 2 | 5 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2017 | clinicaltrials |
| NCT00099047 | Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2016 | clinicaltrials |
| NCT01812720 | Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant(CARAMEL 2) | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 1 | Dec 19, 2016 | clinicaltrials |
| NCT00040937 | S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00306735 | Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation. | completed | Phase 2 | 75 | Eisai Inc.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT00378209 | Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 65 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 17, 2016 | clinicaltrials |
| NCT02756663 | Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma(PANORAMA-5) | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 8, 2016 | clinicaltrials |
| NCT02020941 | Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy | terminated | Phase 2 | 10 | Attaya SuvannasankhaOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02011113 | Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 36 | Celgene CorporationINDUSTRY | 1 | Nov 1, 2016 | clinicaltrials |
| NCT00891618 | Acupuncture for Chemo-Induced Peripheral Neuropathy | completed | Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01699581 | Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant | terminated | Phase 2 | 35 | Greg MonohanOTHER | 1 | Oct 18, 2016 | clinicaltrials |
| NCT02471820 | Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients(RAD) | completed | Phase 2 | 45 | Meletios A. DimopoulosOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT00779922 | Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function | completed | Phase 2 | 39 | Poitiers University HospitalOTHER | 1 | Oct 11, 2016 | clinicaltrials |
Data updated 24 days agoSource updated May 17, 2017source: clinicaltrials